Tumor =< 4 cm maximum diameter, including clinical stage IA and selected IB by positron emission therapy (PET)/computed tomography (CT) scan of the chest and upper abdomen performed within 90 days prior to randomization
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to randomization does not demonstrate metastatic disease and the requirements above are met
Patient must have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy); clinical axillary nodal involvement can be assessed by palpation, ultrasound, CT scan, magnetic resonance imaging (MRI), positron emission tomography (PET) scan, or PET/CT scan
Patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) at any time point between diagnosis of current breast cancer and randomization; screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit; (note positron emission tomography [PET]/CT scan may be used as an alternative imaging technique)
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination by a radiation oncologist (and a surgeon if surgery is planned) within 30 days prior to registration\r\n* Imaging proof of limited metastatic disease and response to therapy/stable disease, by at least diagnostic quality computed tomography (CT) chest through the adrenals or positron emission tomography (PET)/CT, within 30 days prior to registration.
Pathologic stage T3-4 or N1-3 or T1-2, N0 with a close (=< 1 mm) or microscopically positive surgical margin (American Joint Committee on Cancer [AJCC], 7th edition); patients must be free of distant metastases based upon the following minimum diagnostic workup:\r\n* History/physical examination within 8 weeks prior to registration\r\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to registration; at a minimum, contrast computed tomography (CT) imaging of the chest is required; positron emission tomography (PET)/CT is acceptable
Patients must have undergone radical hysterectomy (open, laparoscopically or robotic) and staging including pelvic node sampling or dissection for cervical carcinoma within 70 days prior to study entry (NOTE: if the patient did not have a para-aortic lymph node sampling/dissection, but had common iliac node dissection that was negative, a positron emission tomography [PET]-computed tomography [CT] is recommended, but not required; a negative pre or post-operative PET scan or PET-CT scan of the para–aortic nodes is required if the patient did not undergo para-aortic or common iliac nodal sampling/dissection)
Patients must be clinically staged according to the 7th edition (2010) of the American Joint Committee on Cancer (AJCC) staging system and must have either clinical T3-4a, or >= N1 disease; staging should include upper endoscopy with endoscopic ultrasound and a fludeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) scan (with diagnostic CT abdomen/pelvis preferred)
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, magnetic resonance (MR) spectroscopy, or surgical/pathological documentation of disease
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). For subjects with treated central nervous system (CNS) disease, a head CT and/or brain/spinal magnetic resonance imaging (MRI) as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria.
Subjects may have completed concurrent chemoradiation with a standard chemotherapy regimen (cisplatin/etoposide, carboplatin/paclitaxel or cisplatin/pemetrexed [non-squamous only]) and a dose of radiation ranging from 59.4-66.6 Gy; subjects must have stable disease or disease response as evidenced on computed tomography (CT) or positron emission tomography (PET) scan evaluation; for those eligible, protocol therapy should begin a minimum of 28 days and a maximum 56 days following the completion of chemoradiation\r\nOR\r\nSubjects may have completed up to 2 cycles of consolidation therapy started within 4 weeks of completion of radiation; after completion of consolidation chemotherapy, subjects must have stable disease or disease response as evidenced by CT or PET scan evaluation; for those eligible, protocol therapy should begin 3-4 weeks after the last cycle of chemotherapy
Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to treatment; at a minimum, chest x-ray is required; computed tomography (CT) imaging of the chest or positron emission tomography (PET/CT) is acceptable
Achieved at least stable disease to salvage treatment determined by positron emission tomography (PET)/computed tomography (CT) using 2014 Lugano Classification prior to ASCT
Metastasis that is > 10 mm in longest dimension or exhibits radiotracer uptake consistent with metastasis on positron emission tomography/computed tomography (PET/CT)
fluorodeoxyglucose (FDG)-avid lymphoma (i.e., positron emission tomography (PET)-positive lymphoma)
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) scans are required for full staging of metastatic disease prior to enrollment; if subject has had an FDG-PET/computed tomography (CT) scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: biopsy does not have to be performed at the time of enrollment for patients with recurrent disease as long as biopsy was performed at time of initial diagnosis
Pathologically (histologically or cytologically) proven diagnosis of solid malignancy within 8 weeks of registration\r\n* NOTE: fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scans are required for full staging of metastatic disease; if subject has had an FDG-PET/CT scan within the last 8 weeks, it will not need to be repeated\r\n* NOTE: pathological confirmation is not required for all disease sites as long as the sites of metastatic disease are radiographically and clinically consistent with metastatic disease from a known (biopsy proven) primary\r\n* NOTE: the primary site does not have to be the site of pathological confirmation; for example, in a patient with a radiographic lung lesion with mediastinal lymphadenopathy and a liver lesion, a liver biopsy which is constant with lung primary would preclude the necessity for further pathologic diagnosis
Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration including resting heart rate;\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration; \r\n* Forced expiratory volume in one second (FEV1) >= 0.8 liter or >= 35% predicted with or without bronchodilator within 90 days prior to registration;\r\n** Patients who meet the criterion above without oxygen (O2), but who need acute (started within 10 days prior to registration) supplemental oxygen due to tumor-caused obstruction/hypoxia are eligible, provided the amount of the O2 needed has been stable
Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan
Absence of distant metastases on standard diagnostic work-up =< 16 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], or positron emission tomography [PET]/CT)
Detectable disease by at least one of the following modalities: computed tomography (CT), positron emission tomography (PET), bone scan, or magnetic resonance imaging (MRI)
Non-secretors must have measurable disease such as plasmacytomas, or positron emission tomography (PET) avid lytic lesions or bone marrow plasmacytosis >= 30% at the time of relapse to be eligible
Positron emission tomography (PET) scan is suggested for a PSA >= 0.2 ngs/ml
No clinical evidence of metastatic spread; staging should include endoscopic ultrasound and positron emission tomography (PET)/computed tomography (CT) as recommended by National Comprehensive Cancer Network (NCCN) guidelines; PET/CT should be performed within 3 weeks of signing informed consent
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography (CT) or staging laparoscopy
Staged by positron emission tomography (PET)/computed tomography (CT) and esophagogastroduodenoscopy (EGD) OR CT without (w/) contrast and EGD to have stage II or III disease; endoscopic ultrasound (EUS) is encouraged but not required
Measurable disease, meaning at least 1 lymph node or other lymphomatous lesion with a long axis of ? 1.5 cm by computed tomography (CT) imaging, and at least one fluorodeoxyglucose (FDG)-avid lesion by FDG-positron emission tomography (PET) scan
If solitary lesion, metastasis confirmed with either biopsy or two independent imaging modalities (i.e. CT and PET [positron emission tomography], bone scan and MRI, modality at the discretion of the treating physician)
Metastatic prostate cancer (M1) as documented by appropriate medical imaging (i.e. computed tomography [CT]-scan, positron emission tomography [PET] scan or bone scan)
Positron emission tomography (PET)-computed tomography (CT) within the last 60 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
Staging positron emission tomography (PET)/computed tomography (CT) (invasive mediastinal staging strongly encouraged but not required)
Patients must have a tissue diagnosis of diffuse large B cell lymphoma, with a negative positron emission tomography (PET)/computed tomography (CT) scan performed within 28 days of study enrollment, with one of the following clinical features: \r\n* High risk international prognostic index (IPI)\r\n* Activated B-cell–like (ABC)-subtype DLBCL\r\n* Double hit/ triple hit DLBCL
For Arm G, patients with disease beyond the pelvis, including but not limited to the para-aortic nodes as determined by positron emission tomography (PET)/CT will be excluded.
Positron emission tomography (PET)-computed tomography (CT) within the last 45 days showing radiographic stage I to IIIa lung cancer (mediastinal staging biopsy is allowed but not required)
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Surgically resectable (T1-3 Nx by endoscopic ultrasound); excluded are:\r\n* Very early stage tumors (T1N0)\r\n* Cervical esophageal tumors\r\n* Tumors invading the tracheobronchial tree or associated with tracheoesophageal fistula\r\n* Any evidence of distant metastases (as determined by endoscopic ultrasound [EUS] or computed tomography/positron emission tomography [CT/PET])\r\n* Cervical, supraclavicular, or other nodal disease that is either not included in the radiation field or is not able to be resected at the time of esophagectomy
The patient is staged with endoscopic ultrasound (EUS)/esophago-gastro-duodenoscopy (EGD) and positron emission tomography (PET)/computed tomography (CT) scan
Clinically stage I disease by American Joint Committee on Cancer (AJCC) 7th edition (N0, M0, T stages T1-T2a) or patients with stage T2bN0M0 disease (clinical stage IIA), as determined by a computed tomography (CT) chest, abdomen, pelvis or a positron emission tomography (PET) CT =< 60 days of treatment start, who are medically unfit for standard of care chemotherapy as documented by a medical oncologist or radiation oncologist, or who refuse standard of care chemotherapy as documented by a medical oncologist or radiation oncologist
Staging by positron emission tomography (PET)-computed tomography (CT) scan (required) and magnetic resonance imaging (MRI) brain (if clinically indicated) showing no evidence of metastatic disease (mediastinoscopy is not required unless imaging is indeterminate and is then considered standard of care)
Positive 68Ga-PSMA-11 PET/CT (positron emission computed tomography ) or diagnostic 177Lu-PSMA-617 scintigraphy
Patients with Stage IV breast cancer are not eligible; baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms); if performed, reports of these examinations must be available; examination type for staging, i.e. X-ray, sonography, bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)-CT, is at the discretion of the investigator
Pathologically confirmed diagnosis of relapsed or refractory B-cell acute lymphoblastic leukemia/lymphoma with measurable bone marrow lymphoblasts or biopsy-proven extramedullary site measurable by computed tomography (CT) or positron emission tomography (PET)/CT imaging; Philadelphia chromosome-positive (Ph+) B-ALL patients must have failed treatment with at least one second generation tyrosine kinase inhibitor; prior allo-HCT is allowed
MRI of the pelvis or positron emission tomography (PET)-CT within 4 months before registration
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Patients must not have evidence of metastatic disease per positron emission tomography (PET)/ computed tomography (CT) scan; mediastinal lymph node involvement is acceptable
Patients must have received prior radiation therapy and must have an interval of greater than or equal to 12 weeks (84 days) from the completion of radiation therapy to study entry except if there is unequivocal evidence for tumor recurrence (such as histological confirmation or advanced imaging data such as positron emission tomography [PET] scan) in which case the principal investigator’s discretion may determine appropriate timepoint at which study therapy may begin
Have undergone a second-look surgery by a MD Anderson Gynecologic Oncology faculty after having achieved a complete clinical response to frontline surgery and adjuvant chemotherapy as evidenced by\r\n* Normal physical exam,\r\n* Normal computed tomography (CT) or positron emission tomography (PET)-CT of abdomen and pelvis or other equivalent imaging, and\r\n* Normalization of CA125 (< 35 U/mL)
Low-volume lung metastases are defined as solid pulmonary nodules < 2 cm with non-spiculated contours, no benign-appearing calcifications, and =< 14 in number, diagnosed by computed tomography of the chest or positron emission tomography (PET)
Radiographic evidence of disease other than liver and lungs, with the exception of mediastinal lymph nodes < 2 cm and hepatoduodenal ligament lymphadenopathy, diagnosed by computed tomography, magnetic resonance imaging, or positron emission tomography
Baseline imaging with an fludeoxyglucose (FDG)-positron emission tomography (PET) scan negative for distant metastatic disease must be obtained =< 28 days prior to registration
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Detectable positron emission tomography (PET)-positive disease
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging MRI]) disease documented after completion of prior systemic therapy
Any MPM histology (epithelial, mixed, sarcomatoid)\r\n* N0 or N1 nodal disease as present on preoperative chest computed tomography (CT) and/or positron emission tomography (PET)-CT\r\n* N2 nodule disease if no progression after 2 cycles of standard chemotherapy; progression will be considered if additional N1 or N2 disease develop during chemotherapy
Patients must have at least one bi-dimensionally measurable lesion by palpation, clinical exam, or radiographic imaging within 6 weeks of the start of study intervention (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Pathologic confirmation of NSCLC diagnosis is recommended whenever possible; this will generally be accomplished using computed tomography (CT) guided or bronchoscopic biopsies; if pathologic confirmation is not possible, a target lesion must be a non calcified pulmonary nodule that is present on at least 2 imaging studies (can include simulation scan); the nodule must have increased in size or proportion of solid component on CT and/or show increased fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) over at least 2 imaging studies
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new central nervous system (CNS) lesions are present, patient must have definitive treatment (including surgery or radiation); principal investigator (PI) or his designee should make final determination regarding enrollment
Patients must have documentation of relapse that includes either doubling of CA125 serum levels confirmed by measurements greater than one week apart or identification of a new measurable lesion greater than 1 cm in the peritoneal cavity either by computed tomography/magnetic resonance imaging (CT/MRI), positron emission tomography (PET)/CT scan or physical exam (expanding pockets of ascites fluid that may serve as an alternative source of tumor cells) if the index lesion is not accessible for biopsy for vaccine formulation; recurrence outside the peritoneal cavity will be accessed using standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria
The subject has documented worsening of disease (progressive disease) at screening compared with a previous computed tomography (CT) scan or magnetic resonance imaging (MRI) image done within 14 months of screening documentation of progression may be made by radiological (CT, MRI, or positron emission tomography [PET]), clinical or serological  assessment; if documentation is radiological, screening scan be compared to any previous scan (CT, MRI or PET) within 14 months of cycle 1 day 1 (C1D1)
Patients must have a positron emission tomography (PET) scan within 56 days of enrollment
Patients with prior therapy that included interstitial brachytherapy, or Gliadel wafers must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical documentation of disease
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Clinical T-stage (prior to systemic therapy, if applicable) >= T3a and/or positive lymph nodes by transurethral resection of bladder tumor (TURBT)/magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET)-CT or
Subjects must be diagnosed with either oropharyngeal or supraglottic squamous cell carcinoma\r\n* Primary tumor staging at T1, T2, or T3 based on contrasted neck computed tomography (CT), complete physical exam, and direct laryngoscopy; if possible, a positron emission tomography (PET) CT should also be collected; regardless of size, primary tumors must be mobile on physical exam and must not exhibit invasion of parapharyngeal fat on CT\r\n* Regional nodal metastases stages as N0, N1, or N2 without extracapsular spread (ECS)\r\n** N2a immediately eligible\r\n** N2b and N2c eligible when nodes are isolated (i.e., no conglomerate nodal masses)\r\n* No evidence of distant metastatic disease
Histologically confirmed adenocarcinoma of the pancreas or ampulla of Vater; at least the majority of the histopathologic specimen must be identified as adenocarcinoma as opposed to another histologic subtype\r\n* If histological confirmation of adenocarcinoma cannot be obtained by biopsy, the following procedures may be employed:\r\n** Attempt a repeat biopsy to obtain a diagnosis\r\n** Present the case at John Hopkins University (JHU) tumor board and if the candidate has one of the following: a rising cancer antigen (CA) 19-9 or radiographic evidence of recurrence on magnetic resonance imaging (MRI), computed tomography (CT), and/or positron emission tomography (PET) scan then the patient can be considered for treatment on protocol\r\n* However, if these objectives cannot be met, the patient will not be a candidate
Patients must receive a magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) of the brain within 6 months of signing informed consent; if new lesions are present, patient must have definitive treatment; principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Locally advanced high-risk carcinoma of the uterine cervix, i.e.: intact cervix (i.e. non-operative) with International Federation of Gynecology and Obstetrics (FIGO) stage at least IB2 OR post-hysterectomy with either: residual gross disease or para-aortic nodal involvement (either resected or unresected) based upon standard diagnostic workup, including:\r\n* History/physical examination \r\n* Examination under anesthesia (if indicated)\r\n* Biopsy \r\n* Intravenous pyelogram and/or cystoscopy (if indicated)\r\n* Colonoscopy, sigmoidoscopy, or rigid proctoscopy (if indicated)\r\n* Posteroanterior (PA) and lateral chest x-ray or chest computed tomography (CT)\r\n* CT or magnetic resonance imaging (MRI) of the pelvis\r\n* Positron emission tomography (PET), PET/CT, or PET/CT simulation (encouraged)
Relapse/persistent disease evidenced by a computed tomography and fluorodeoxyglucose (FDG)-positron emission tomography (PET), or bone marrow biopsy
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical/pathological documentation of disease
Clinical stage II and III NSCLC based on American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to document nodal positivity include computed tomography (CT) chest, positron emission tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI)
No evidence of distant metastatic disease as documented by magnetic resonance imaging (MRI) of the brain and positron emission tomography (PET)/computed tomography (CT)
Patients must receive an magnetic resonance imaging (MRI)/computed tomography (CT) of the brain or positron emission tomography (PET)/CT within 6 months of consenting; if new lesions are present, principal investigator (PI) or his designee should make final determination regarding enrollment (Turnstile I)
Patients are eligible for transplantation if there is no evidence of progressive disease by imaging modalities or biopsy; persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Evidence of progressive disease by imaging modalities or biopsy-persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Staging evaluation within 42 days of enrollment consisting of staging laparoscopy, computed tomography (CT) scan of the abdomen and pelvis, and positron emission tomography (PET) scan will be acquired; also endoscopic ultrasound (EUS) tumor and nodal staging will be required
Positron emission tomography (PET)-positive disease
Bone scan within 120 days prior to enrollment; if the bone scan is suspicious, a plain x?ray and/or MRI must\r\nbe obtained to rule out metastasis, and advanced imaging (e.g., 18NaF positron emission tomography [PET]/CT) is strongly recommended
Must have pathologically-proven adenocarcinoma of the stomach or gastroesophageal (GE)-junction, stage M0, as established by both imaging and surgical pathologic staging.\r\n* Imaging: Clinical stage of M0 will be established by either computed tomography (CT) (chest with contrast and abdomen/pelvis with and without contrast), or CT/positron emission tomography (PET) (skull base to mid-thigh). This is standard post-surgery imaging.\r\n*Surgery: Surgical pathologic staging must be M0.
Must have American Joint Committee on Cancer (AJCC) 7th edition (ed) inoperable stage II disease requiring chemoradiation therapy or stage IIIA or IIIB NSCLC based on appropriate staging studies including brain magnetic resonance imaging (MRI) or head computed tomography (CT), CT chest, and fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan
Patients must demonstrate >= 75% disease reduction on computed tomography (CT) scan (confirmed by positron emission tomography [PET] scan) after the third cycle of R-EPOCH relative to baseline, with no evidence of disease progression after the fifth cycle
Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, positron emission tomography [PET]-CT, or PET scan) performed within 6 weeks prior to randomization does not demonstrate metastatic disease and the requirements are met
Patients must undergo pre-treatment endoscopic tumor staging and positron emission tomography (PET)-computed tomography (CT) scanning
All responses are to be determined using the response criteria for non-hodgkin’s lymphoma and will include PET/computed tomography (CT) prior to hematopoietic cell transplantation (HCT)
Fluorodeoxyglucose (FDG)-avid disease by positive emission tomography (PET), and measurable disease greater than 1.5 cm in diameter
A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
Fluorodeoxyglucose-avid disease by positron emission tomography and measurable disease greater than 1.5cm diameter
pathologically confirmed mantle cell lymphoma (MCL), with (a) measurable nodal disease on positron emission tomography computed tomography (PET-CT) per Lugano classification. Prior to enrollment, pathology must be reviewed and confirmed at the investigational site where the participant is entered
Subjects with HL with no available curative treatment options (such as autologous stem cell transplant [SCT]) who have a limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled\r\n* HL with biopsy-proven relapse or refractory disease who are unresponsive to or intolerant of at least one line of standard salvage therapy\r\n* Patients must have evaluable disease by radiologic imaging (fluorodeoxyglucose [FDG] positron emission tomography [PET]/computed tomography [CT] or PET/magnetic resonance imaging [MRI]) within 42 days of enrollment; evaluable includes both assessable and/or measurable disease as defined by Cheson et al., 2007
Metastatic lesions identifiable only by positron emission tomography (PET)
Patients must have a magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) of the brain within 2 months before consenting if known history of brain metastasis or if clinically indicated; if new lesions are present, principal investigator (PI) or designee should make final determination regarding enrollment
Subjects must have measurable or evaluable disease based on physical exam and/or radiographs (computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]) or bone marrow involvement
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon positron emission tomography (PET), Thallium scanning, MR spectroscopy/perfusion, progression outside of radiation field, or surgical documentation of disease; if the additional imaging is unable to be performed for insurance or other reasons, the principal investigator (PI) will review the available imaging to determine if patients is eligible
Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging [MRI]) disease documented after completion of prior systemic therapy
Presence of evaluable disease by positron emission tomography (PET) imaging per the Lugano classification
Histologically confirmed adenocarcinoma of the prostate with progressive metastatic disease which, in the opinion of the investigator, requires initiation of new treatment. The assessment of disease progression can be based on either PSA rise, new or progressive soft tissue disease (based on computed tomography [CT] or magnetic resonance imaging [MRI] scans), or new or progressive bony disease based on radionuclide bone scan or 18F-sodium fluoride positron emission tomography/computed tomography [NaF PET/CT] scans). Participants being considered for Cohort 2B must, in addition, have primary or metastatic lesions amenable to tumor biopsies
Standard staging exams for patients with high-risk prostate cancer including bone scan or sodium fluoride (NaF) positron emission tomography (PET)/CT scan, and pelvic and prostate MRI
Evidence of metastatic disease\r\n* NOTE: patients will not require baseline staging positron emission tomography (PET) or computed tomography (CT) chest, abdomen, pelvis or bone scan to rule out metastatic disease prior to enrollment; any staging scans will be ordered at the treating provider’s discretion; if metastatic disease is found on any staging studies done, patients will not be eligible for enrollment
ELIGIBILITY FOR TREATMENT ON ARM 1: Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (X-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
clinical and laboratory signs: rapid disease progression, high standardized uptake value (SUV) (> 12) by positron emission tomography (PET) at baseline if PET scans are performed (optional).
Histologic proof of stage II, III or IV melanoma that has been completely resected or completely treated with ablative therapy (ex: stereotactic body radiosurgery, radiofrequency ablation, cryoablation) with no current evidence of disease, as demonstrated by imaging within 2 months (61 days: stage IIIB, IIIC or stage IV; must be computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography [PET]/CT) or 6 months (183 days: stage II or IIIA; may be chest x-ray, CT, MRI, or PET/CT)
Staging studies with a computed tomography (CT) scan of the chest and abdomen and bone scan, or a positron emission tomography (PET)/CT is required for clinical stage III, and are considered optional for stage II breast cancers
Appropriate stage for protocol entry based upon the following minimum diagnostic workup:\r\n* History/physical examination within 30 days prior to registration\r\n* Fludeoxyglucose F 18 (FDG)-positron emission tomography (PET)/computed tomography (CT) scan for staging within 60 days prior to registration\r\n* Magnetic resonance imaging (MRI) scan with contrast of the brain (preferred) or CT scan of the brain with contrast within 60 days prior to registration
Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging (MRI) of brain and orbits with and without gadolinium; MRI may be done within 21 days prior to study entry\r\n* Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone scan (or fludeoxyglucose F-18 [FDG] positron emission tomography [PET] scan), and/or any other additional tests done at study entry; (Note: these tests are required only with specific indications for required observations)
Distant metastatic disease limited to peritoneum and radiologically occult (not visualized on preoperative imaging to include [computerized tomography] CT scan, ultrasound, [magnetic resonance imaging] MRI, positron emission tomography [PET]/CT): \r\n* Positive peritoneal cytology\r\n* Carcinomatosis on diagnostic laparoscopy or laparotomy
Patients can have up to only 6 discrete active extracranial lesions (=< 3 in the liver and =< 3 in the lung) identified by diagnostic computed tomography (CT) or positron emission tomography (PET)/CT scan or magnetic resonance imaging (MRI) within 8 weeks prior to the initiation of SBRT\r\n* For patients who have received prior radiotherapy to the primary site in the lung, residual PET activity is difficult to interpret and will not be considered a site of active disease if the CT appearance is stable or improved over an interval of at least three months\r\n* Patients who previously received radiotherapy to the primary site will be ineligible if there is CT evidence of disease progression within the past 3 months\r\n* Patients with previously un-irradiated primary sites will be potentially eligible, but special considerations apply\r\n* Up to 2 contiguous vertebral metastases will be considered a single site of disease
Positron emission tomography (PET)/CT, x-ray or CT-scan of chest showing no evidence of metastatic disease
Absence of distant metastases on standard diagnostic work-up =< 10 weeks prior to registration; (chest computed tomography [CT], chest x-ray [CXR], positron emission tomography [PET]/CT, etc.)
Patients with prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease rather than radiation necrosis based upon either positron emission tomography (PET) or thallium scanning, MR spectroscopy or surgical/pathological documentation of disease
Complete radiology or tumor assessment within 28 days of randomization\r\n* Breast magnetic resonance imaging (MRI)\r\n* Unilateral breast ultrasound\r\n* Distant metastatic work-up completed with positron emission tomography (PET)/computed tomography (CT) or CT chest, abdomen, pelvis and bone scan\r\n* If enlarged axillary lymph nodes are found during staging scans, fine needle aspiration (FNA) must be performed to determine whether the node is involved with cancer\r\n* If axillary lymph nodes are clinically negative during initial work-up, sentinel node biopsy may be performed prior to initiation of chemotherapy
Patients with DLBCL had a positive [18F]fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at baseline (Cheson response criteria)
Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine which may include computer assisted tomography (CAT scan), positron emitted tomography (PET) or nuclear medicine bone scan (NMBS); magnetic resonance imaging (MRI) is required prior to treatment planning to confirm the extent of the disease and is used for defining the target for the radiation
Metastatic disease on bone scan and/or involvement of soft tissues (lymph nodes and/or viscera) by computed tomography (CT) scan, positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)
Patients must have been evaluated by standard-of-care full body imaging studies (computed tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction HDI-ipilimumab (at 6-8 weeks after the first dose of ipilimumab/HDI and prior to the definitive lymphadenectomy procedure)
Systemic involvement (i.e., nodal, bone marrow or visceral organ involvement) will be evaluated by computed tomography (CT) and/or positron emission tomography (PET) and bone marrow biopsy (if indicated on patients with blood involvement) in patients with pc-ALCL or MF at baseline
Deauville score of 1-3 on post-chemotherapy (or interim) positron emission tomography (PET) scan
Appropriate stage for study entry based on the following diagnostic workup:\r\n* History/physical examination within 30 days prior to registration;\r\n* Imaging of the primary tumor by MRI and/or computed tomography (CT) with and without contrast and/or positron emission tomography (PET)/CT within 60 days prior to registration;\r\n* Staging workup evaluated by chest CT and/or PET/CT showing no distant metastasis within 60 days prior to registration
All oncologists and radiologists will review positron emission tomography (PET) scans prior to therapy as standard practice to confirm eligibility
Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by:\r\n* EITHER computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen and pelvis, OR endorectal MRI of the pelvis that demonstrate no nodes > 1.5 cm\r\n* If one or more pelvic lymph node(s) measures > 1.5 cm, a negative biopsy is required; if more than one lymph node is > 1.5 cm, the largest or most accessible node should be biopsied; AND\r\n* Negative bone scan (with plain films and/or MRI and/or CT scan confirmation, if necessary)\r\nPositive positron emission tomography (PET) and ProstaScint scans are not considered proof of metastatic disease
Positron emission tomography (PET)/computed tomography (CT) is required for all patients, unless contraindicated; this may be acquired prior to study entry or after enrollment prior to SBRT planning
Metastatic disease beyond the neck or supraclavicular area as demonstrated by positron emission tomography (PET)/CT or biopsy
Bi-dimensionally measurable disease by palpation, clinical exam, or radiographic imaging (x-ray, computed tomography [CT] scan, positron emission tomography [PET] scan, magnetic resonance imaging [MRI], or ultrasound)
Patient must have histologically proven primary or recurrent extremity melanoma, stage IIIB, IIIC, or stage IV (American Joint Committee on Cancer [AJCC] staging must be documented in patient’s medical record, as determined by computed tomography [CT] of the chest, abdomen and pelvis, and/or whole body positron emission tomography [PET] scan, and magnetic resonance imaging [MRI] of the brain within 4 weeks prior to administration of study drug)
Patients must have been evaluated by standard-of-care full body imaging studies (computerized tomography [CT], positron emission tomography [PET]-CT or magnetic resonance imaging [MRI]) as part of the initial clinical work-up at baseline (no more than 4 weeks prior to study enrollment) and after completion of induction nivolumab-ipilimumab or nivolumab alone (at 6-8 weeks after the first dose of induction and prior to the definitive surgery procedure)
Fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET).
Fluorodeoxyglucose positron emission tomography (FDG-PET) avid disease on baseline scan For enrollment in part 2, patients must meet all of the following:
Patients must have pathologic diagnosis of non-small cell lung carcinoma (NSCLC), by either histologic biopsy, or cytologic evidence; highly suspicious cytology (i.e. abnormal cells suspicious for malignancy) is acceptable, in the setting of a strongly positive computed tomography (CT)/positron emission tomography (PET) (standardized uptake value [SUV] > 5.0)
Systemic staging including computed tomography (CT) that covers the chest, liver and adrenal glands or a positron emission tomography (PET)/CT; magnetic resonance imaging (MRI) of the brain is required and must be negative for metastatic spread; if a patient is unable to tolerate MRI or has a contraindication to MRI, a head CT scan with and without contrast is acceptable
There must be an interval of at least 12 weeks from the completion of radiotherapy to start of device treatment; when the interval is less than 12 weeks from the completion of radiotherapy, the histological confirmation of progression must be unequivocal per Revised Assessment in Neuro-Oncology (RANO) criteria; the use of positron emission tomography (PET) scan, perfusion imaging, and magnetic resonance (MR) spectroscopy to differentiate between true early progression and pseudoprogression prior to biopsy or resection of probable recurrent tumor is per standard of care
No evidence of metastatic disease on imaging by whole body bone scan (technetium-99 or sodium fluoride [Na-F] positron emission tomography [PET] bone scan) and cross-sectional imaging of the abdomen/pelvis (computed tomography [CT] or magnetic resonance imaging [MRI]) within 6 weeks of day 1 of protocol therapy
N2-3 lymph node involvement based on positron emission tomography (PET)/endobronchial ultrasound-fine needle aspiration (EBUS-FNA)/mediastinoscopy (any N2 disease that is more than just minimal single station involvement is excluded)
Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ? 3) systemic disease (using Lugano Classification response criteria) by positron emission tomography (PET)-diagnostic computed tomography (CT). Baseline scans must be of acceptable quality to the central radiology laboratory prior to Cycle 1 Day 1.
Patients must have failed prior external beam radiation therapy; a positron emission tomography (PET) or thallium single photon emission computed tomography (SPECT), MR spectroscopy and MR perfusion, or surgical documentation may be done at the discretion of the treating physician if there is a question of radiation changes/necrosis versus progressive disease
Have no evidence of distant metastases (as determined by endoscopic ultrasound [EUS], PET-computed tomography [CT] or staging laparoscopy)
Positron emission tomography (PET) avid disease with standard uptake value (SUV) > 5
Centers that standardly use positron emission tomography (PET) or magnetic resonance spectroscopy (MRS) to determine a diagnosis of radionecrosis are permitted to use these modalities to assist in their patient selection; however the criteria described for conventional MR and/or DSC should also be met for study eligibility; both PET and MRS are not mandatory for study eligibility
Patients must have no evidence of metastasis on positron emission tomography (PET) scan or magnetic resonance imaging (MRI) or computed tomography (CT) scan of the pelvis and chest imaging
Patients with any radiographic evidence of metastases, including plain x-ray, bone scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, or positron emission tomography (PET) scan
Patients must have cross-sectional body imaging (positron emission tomography [PET]-computed tomography [CT] or equivalent) performed within 4 weeks of study enrollment and available for review
Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid tumors
The patient has received a clinical classification of stage I or II disease; \clinically classified\ means using all studies including computed tomography (CT) scans, positron emission tomography (PET) scans, bone scans, mediastinoscopy, and/or any study or procedure performed short of thoracotomy
Subjects must have had a baseline scan (computed tomography [CT], magnetic resonance imaging [MRI], or positron emission tomography-computer tomography [PET/CT]) of the chest to assess disease burden before starting on first line chemotherapy for NSCLC and those images must have been reviewed by the investigator prior to randomization. If the scan was performed more than 28 days prior to randomization, an additional scan must be performed and reviewed by the investigator to confirm that the patient has not progressed before randomization.
No evidence of relapsed or residual malignancy within 30 days of trial entry; all patients must undergo appropriate staging for their malignancy (i.e. bone marrow aspiration for the leukemias and positron emission tomography [PET]-computed tomography [CT] scanning for the lymphomas); evidence of a persistent cytogenetic abnormality will constitute evidence of residual or relapsed disease in the leukemias, where present; individuals with chronic lymphocytic leukemia (CLL) are eligible if there is no more than 20% residual leukemia in the bone marrow at the time of study entry
NHL\r\n* No clinical evidence of disease or disease-related symptoms\r\n* Typically fludeoxyglucose (FDG)-avid lymphomas: a post-treatment residual mass of any size is permitted as long as it is positron emission tomography (PET) negative\r\n* Variably FDG-avid lymphoma/FDG avidity unknown: all lymph nodes normal size by computed tomography (CT)\r\n* Spleen and liver non-palpable and without nodules\r\n* If pretreatment bone marrow biopsy was positive, repeat bone marrow biopsy must be negative; if morphologically indeterminate, immunohistochemistry should be negative
Evidence of progressive disease by imaging modalities or biopsy - persistent positron emission tomography (PET) activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of computed tomography (CT) changes indicating progression
Subject must have positron emission tomography (PET)-positive disease as per Lugano Classification
N2 lymph nodes negative on positron emission tomography (PET) scan or mediastinoscopy
Participants must have no evidence of nodal involvement (N0) or distant metastases (M0) on staging studies, which may include positron emission tomography (PET), computed tomography (CT), and/or mediastinoscopy
Patients with known or suspected neuroblastoma or pheochromocytoma are eligible. 18F-DA PET/computed tomography (CT) scanning will not be the initial imaging study in a newly diagnosed patient
Stage T1-4aN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* Computed tomography (CT) chest/abdomen with contrast \r\n* Positron emission tomography (PET)/CT of the whole-body or skull base to mid-thigh\r\n* Patients must have regional adenopathy and have undergone endoscopic biopsy with endoscopic ultrasound (EUS)-proven peri-esophageal nodal involvement
Diagnosis of extensive stage disease (extensive stage [ES]-SCLC), with stage established by computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scan
Patients that have early stage non-small cell lung cancer or clinical suspicion of the same in cases where the lesion is not amenable to biopsy but is enlarging and positron emission tomography (PET)-positive; all patients are to be treated with stereotactic body radiation therapy as a monotherapy
Negative pregnancy test within 7 days of baseline positron emission tomography (PET) scan for pre-menopausal patients
Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm in diameter on axial imaging (CT or MRI or positron emission tomography [PET]/CT)